Kumar, N.; Teague, B.; Paine, P.; Mukerjee, S.; Higham, A.; Brown, C.; Stewart, A.; Askew, T.; Davies, A.; Polland, M.; Keating, J.
April 2003
Gut;Apr2003 Supplement 1, Vol. 52, pA107
Academic Journal
Current recommendations, including NICE guidance, suggest treating genotype I hepatitis C with combination treatment for 12 months and genotype II/III for 6 months. However, this prolonged course of treatment puts enormous strain on budgets, thereby limiting its use and the length of this treatment reduces compliance. Our prospective study recruited 51 patients, following ethics committee approval, of whom 33 (65%) were male and 18 (35%) were female, age range 22-56 years. 44% were genotype I and 56% were genotype II/III. The majority of these patients (80%) had mild to moderate hepatitis as assessed by the Ishak scoring system. 4 (8%) had severe hepatitis and 6 (12%) had cirrhosis. They received 3 months of combination treatment, consisting of weekly PEG interferon 1.5 mcg/kg and Ribavarin 400 mgm twice daily. To improve compliance PEG interferon was given either at the hepatology clinic, or at the GP's surgery. Monthly PCR testing assessed their response to treatment. We achieved 96% compliance. Treatment in one patient had to be temporarily stopped due to severe anaemia. The side effect profile in our study was similar to other major studies. Surprisingly our patients with leucopenia responded well to dose modification. At the end of 3 months treatment 70% of genotype II/ill and 52% of genotype I were hepatitis C PCR negative. Non-responders were treated with a further course of treatment as per NiCE guidance. This study shows that 3 months treatment may be adequate in the majority of patients with mild to moderate hepatitis C. This shortened course of treatment would improve compliance, reduce side effects, and have a major impact on the economy of treating this condition, thereby making this treatment widely available.


Related Articles

  • Efficacy and safety of 6-month iron reduction therapy in patients with hepatitis C virus-related cirrhosis: a pilot study. Tanaka, Naoki; Horiuchi, Akira; Yamaura, Takahiro; Komatsu, Michiharu; Tanaka, Eiji; Kiyosawa, Kendo // Journal of Gastroenterology;Jan2007, Vol. 42 Issue 1, p49 

    Iron reduction therapy (IRT) has been recognized as beneficial for chronic hepatitis C patients. However, its efficacy for hepatitis C virus-related liver cirrhosis (LC-C) has not been elucidated. We evaluated the efficacy and safety of IRT for LC-C patients. Twenty-two LC-C patients were...

  • Hepatitis C Infection: A Rare Cause of Fulminant Hepatic Failure. Gordon, Fredric D.; Anastopoulos, Harry; Khettry, Urmila; Loda, Massimo; Jenkins, Roger L.; Lewis, W. David; Trey, Charles // American Journal of Gastroenterology;Jan1995, Vol. 90 Issue 1, p117 

    Fulminant hepatic failure is caused by a variety of viruses, toxins, and metabolic derangements. The hepatitis C virus (HCV) causes indolent development of cirhosis and has not been associated with fulminant hepatic failure. We report the first documented case of fulminant hepatitis C in the...

  • Antiviral treatment of Hepatitis C Virus Carriers with normal ALT levels: actual utility or unnecessary expense? Puoti, Claudio // British Journal of Medical Practitioners;2011, Vol. 4 Issue 3, p4 

    The author reflects on the treatment of Hepatitis C Virus (HCV) carriers with antiviral agents in case of normal alanine tranferase (ALT) levels. He also comments that during the course of HCV infection, ALT levels fluctuate and presence of chronic hepatitis or cirrhosis is reported. The author...

  • Pegylated interferon promises first effective treatment for hepatitis C and related cirrhosis.  // Formulary;Feb2000, Vol. 35 Issue 2, p125 

    Reports that a pegylated form of interferon alfa-2a induces sustained response in hepatitis C patients with cirrhosis. Liver failure due to chronic hepatitis C and related cirrhosis as the primary reason for liver transplantation in the United States; Functions of the pegylation process;...

  • The Hepatitis C Patient: Functional Assessment and Effective Botanical Remedies. Calvino, Nicholas // Townsend Letter for Doctors & Patients;Dec2002, Issue 233, p74 

    Focuses on the functional assessment and botanical remedies of patient with hepatitis C. Symptoms of the disease; Causes of chronic liver disease; Percentage of hepatitis C patients with cirrhosis.

  • A giant spider nevus in a patient of hepatitis C-related liver cirrhosis: A rare presentation. Sood, Ajit; Gupta, Rahul; Midha, Vandana // International Journal of Applied & Basic Medical Research;Sep-Dec2015, Vol. 5 Issue 3, p206 

    Spider nevi are benign vascular lesions mostly seen in patients with decompensated liver cirrhosis. Mostly, these are seen in the superior vena cava distribution and are small with pinhead size central vessel. Giant spider nevus is rarely seen and hence this report.

  • Long Term Follow up of Interferon Treated Chronic HCV Patients in Responders and Non-Responders. Sajjad, Shaimuna Fareeha; Ahmed, Waquaruddin; Arif, Ambreen; Alam, Syed Ejaz // Pakistan Journal of Medical Research;Jul-Sep2015, Vol. 54 Issue 3, p69 

    Background: Interferon with ribavirin is the recommended treatment for chronic hepatitis C with a response rate ranging from 50-80% in different countries. Although sustained response is comparable to clinical cure, but whether interferon therapy slows down the disease process in non-responders...

  • Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders. Cozen, Myrna; Ryan, James; Shen, Hui; Cheung, Ramsey; Kaplan, David; Pocha, Christine; Brau, Norbert; Aytaman, Ayse; Schmidt, Warren; Pedrosa, Marcos; Anand, Bhupinderjit; Chang, Kyong-Mi; Morgan, Timothy; Monto, Alexander; Cozen, Myrna L; Ryan, James C; Kaplan, David E; Schmidt, Warren N; Anand, Bhupinderjit S // Digestive Diseases & Sciences;Jun2016, Vol. 61 Issue 6, p1744 

    Background: As the era of interferon-alpha (IFN)-based therapy for hepatitis C ends, long-term treatment outcomes are now being evaluated.Aim: To more fully understand the natural history of hepatitis C infection by following a multisite cohort of...

  • Actualización terapéutica en la hepatitis C. Devesa, María José; Cuenca, Francisca; Izquierdo, Sonia; Sánchez-Pobre, Pilar; Ladero, José María; López-Alonso, Gustavo; Díaz-Rubio, Manuel; Rey, Enrique // Revista Española de Quimioterapia;2015 Supplement, Vol. 28, p48 

    Hepatitis C virus infection is a major health burden affecting 130-170 million people worldwide. Approximately 10-30% of those with chronic hepatitis C will progress to cirrhosis over 20-30 years. The development of new direct-acting antivirals has changed the management of the disease, allowing...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics